Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF) (2018 - 2026)
Fulcrum Therapeutics (FULC) has 9 years of Depreciation & Amortization (CF) data on record, last reported at $338000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 4.25% to $338000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 million, a 12.49% decrease, with the full-year FY2025 number at $1.4 million, down 12.5% from a year prior.
- Depreciation & Amortization (CF) reached $338000.0 in Q1 2026 per FULC's latest filing, down from $400000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for FULC hit a ceiling of $700000.0 in Q2 2022 and a floor of $300000.0 in Q2 2025.
- A 5-year average of $467882.4 and a median of $472000.0 in 2023 define the central range for Depreciation & Amortization (CF).
- Peak YoY movement for Depreciation & Amortization (CF): rose 11.94% in 2023, then tumbled 33.33% in 2024.
- Tracing FULC's Depreciation & Amortization (CF) over 5 years: stood at $600000.0 in 2022, then dropped by 21.33% to $472000.0 in 2023, then fell by 20.34% to $376000.0 in 2024, then rose by 6.38% to $400000.0 in 2025, then decreased by 15.5% to $338000.0 in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for FULC at $338000.0 in Q1 2026, $400000.0 in Q4 2025, and $300000.0 in Q3 2025.